Companies To Watch
-
Companies To Watch: IM Therapeutics
6/1/2021
Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.
-
Companies To Watch: Lyra Therapeutics
5/3/2021
Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.
-
Companies To Watch: Carisma Therapeutics
4/1/2021
Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.
-
Companies To Watch: PhaseBio
3/1/2021
PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.
-
Companies To Watch: Akero Therapeutics
2/1/2021
Companies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH
-
Companies To Watch: Artax Biopharma
1/4/2021
Artax Biopharma is challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.
-
Companies To Watch: Ridgeback Biotherapeutics
10/30/2020
Ridgeback Biotherapeutics is pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses.
-
Companies To Watch: Osivax
10/1/2020
Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.
-
Companies To Watch: CalciMedica
9/1/2020
“In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.
-
Companies To Watch: Cidara Therapeutics
8/3/2020
Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.